Mastodon

Sennaplant® (Tablets) Instructions for Use

Marketing Authorization Holder

Evalar, CJSC (Russia)

ATC Code

A06AB06 (Sennosides A and B)

Active Substance

Senna (BP British Pharmacopoeia)

Dosage Form

Bottle OTC Icon Sennaplant® Tablets 13.5 mg: 20, 40, 60 or 240 pcs.

Dosage Form, Packaging, and Composition

Tablets from brown to gray-brown in color with darker and lighter specks, round, flat-cylindrical, with a score and a bevel; with a mint odor that intensifies when rubbed.

1 tab.
Dry senna leaf extract (15:1)* 93.33 mg,
   Which corresponds to the content of the sum of hydroxyanthracene glycosides calculated as sennoside B 13.5 mg (14.5%)

* Extraction solvent ethanol 70%.

Excipients: microcrystalline cellulose – 58.64 mg, pregelatinized starch – 58.64 mg, croscarmellose sodium – 11.5 mg, talc – 4.6 mg, colloidal silicon dioxide – 2.3 mg, magnesium stearate – 0.7 mg, peppermint leaf oil – 0.29 mg.

20 pcs. – blister packs (1) – cardboard packs.
20 pcs. – blister packs (2) – cardboard packs.
20 pcs. – blister packs (3) – cardboard packs.
20 pcs. – blister packs (12) – cardboard packs.

Clinical-Pharmacological Group

Laxative drug that stimulates intestinal peristalsis

Pharmacotherapeutic Group

Laxative of plant origin

Pharmacological Action

A laxative of plant origin. Senna leaves contain dianthrone glycosides (about 3%) – sennosides A, A1, B-G; a small amount of anthraquinone glycosides, including aloe-emodin and rhein 8-glycosides; about 10% mucilage; flavonoids, including kaempferol derivatives; naphthalene glycosides.

It stimulates peristalsis of the large intestine, causing a normal bowel movement 8-10 hours after administration. It acts selectively on the colon, restores normal bowel function, and does not affect digestion.

Indications

Constipation caused by hypotension and sluggish peristalsis of the large intestine. Regulation of stool in hemorrhoids, proctitis, anal fissures; spastic and atonic constipation of various etiologies.

ICD codes

ICD-10 code Indication
K59.0 Constipation
K60 Fissure and fistula of anus and rectum
K62.8 Other specified diseases of anus and rectum (including proctitis)
K64 Hemorrhoids and perianal venous thrombosis
ICD-11 code Indication
DB32.1 Slow-transit constipation
DB50.Z Fissure or fistula of anal region, unspecified
DB6Z Hemorrhoids or perianal venous diseases, unspecified
DB70.Z Infections of anal and rectal regions, unspecified
DB72.Z Some specified diseases of the anal canal, unspecified
DD91.1 Functional constipation
DE2Z Diseases of the digestive system, unspecified
EG61 Infections of the anus or perianal skin

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take orally in the evening after the last meal.

Swallow tablets whole with a full glass of water.

The standard adult and pediatric dose over 12 years is one to two tablets (13.5 mg to 27 mg) once daily.

For severe constipation, the dose may be increased to four tablets (54 mg).

Do not exceed the maximum single dose of four tablets.

Do not exceed the maximum daily dose of four tablets.

Adjust the dose individually to achieve soft stool once daily.

Use the lowest effective dose for the shortest duration necessary.

The onset of action typically occurs within 8 to 10 hours after administration.

For short-term use only. If constipation persists beyond one week, consult a physician.

Discontinue use immediately if abdominal pain or diarrhea occurs.

Long-term use may lead to laxative dependence and electrolyte imbalance.

Avoid prolonged use; do not use for more than one to two weeks without medical supervision.

Adverse Reactions

Possible allergic reactions, abdominal pain, flatulence, diarrhea; with long-term use – colitis.

Contraindications

Hypersensitivity to senna; intestinal obstruction, abdominal pain of unknown origin, water-electrolyte imbalance, acute inflammatory diseases of the abdominal organs, proctitis and hemorrhoids in the acute stage, strangulated hernia, gastrointestinal bleeding, uterine bleeding, cystitis, spastic colitis, spastic constipation; pregnancy, breastfeeding period; childhood – depending on the dosage form.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and lactation (breastfeeding).

Use in Hepatic Impairment

Use with caution in liver diseases.

Use in Renal Impairment

Use with caution in kidney diseases.

Pediatric Use

Use in children of appropriate age categories is possible strictly according to indications, in recommended doses and dosage forms. It is necessary to strictly follow the instructions in the senna drug leaflets regarding contraindications for use in children of different ages for specific senna dosage forms.

Special Precautions

With long-term use of senna preparations, habituation may develop, so it is advisable to alternate them with other laxatives.

Drug Interactions

Senna preparations reduce the absorption of tetracycline.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS